This study is for adults with a specific type of advanced lung cancer (non-small cell) that has a mutation in the EGFR gene. It aims to see if adding a drug called ramucirumab to the standard drug osimertinib can help control the cancer for a longer time without it getting worse.…
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC